The <em>New York Times</em> reports Fried Frank's role in Celgene's acquisition of Abraxis BioScience

The New York Times reports Fried Frank's role in Celgene's acquisition of Abraxis BioScience

The New York Times noted the Firm's representation of Abraxis BioScience Inc. in connection with its US$2.8b acquisition by Celgene Corporation. The Fried Frank team was led by corporate partners Philip Richter (NY) and Brian T. Mangino (DC) and tax partners Alan S. Kaden (DC) and Michael J. Alter (DC).

news-detail.inc